AI-generated summary
The authors describe a planned randomised, double-blind clinical trial protocol testing photobiomodulation at 630 nm against a sham treatment, both alongside a moisturising cream, to reduce palmar-plantar erythrodysesthesia caused by capecitabine or 5-fluorouracil chemotherapy. The protocol plans to enrol 40 individuals over four weeks, and no results are reported.
- Participants
- 40
- Who or what was studied
- Individuals receiving capecitabine or 5-fluorouracil chemotherapy who develop palmar-plantar erythrodysesthesia
- Wavelengths
- 630 nm
- Limits stated in the abstract
- This is a study protocol only, so no outcomes are reported, and the abstract gives no efficacy results.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on bmjopen.bmj.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630 nm
- Energy density (fluence)
- 4 J/cm2
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Intention-to-treat analysis, Trial registration, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.